Periodic Reporting for period 2 - VR4NEURO (Building the world’s largest digital hospital for neurological challenges)
Reporting period: 2023-11-01 to 2025-03-31
The current care path of different neurological disorders, such as ADHD, Autism, Alzheimer and Aphasia, is resource-intensive and inefficient in diagnosing and treating the patients. There is currently no way to screen larger masses of people effectively. The people that are subjectively observed by themselves, parents, teachers etc. may seek out diagnosis. This subjective observation is not reliable and will fill the limited resources with patients not having neurological diseases and miss a lot of patients that would need help but aren’t observed early. We provide quick and efficient tools to help screen masses and enable patients to move on the care path they need.
In the diagnostics phase, our tools help to reach diagnosis faster and more reliably. At the moment, psychiatrists and doctors utilize slow and inaccurate pen and paper -tests to help make diagnoses. By introducing objective, reliable and accurate diagnostics tools we are able to evolve and improve the diagnosis path greatly.
After screening and diagnostics, the care path moves on to treatment, medication and evaluation. Our innovations help in all of these. Through our web platform, doctors can assess the effect of medication and assess the treatment more accurately and react faster to changes in the patient's performance in their everyday life.
During the project, we have developed a robust tool to help diagnosing and rehabilitate patients. The project allowed us to put product development on the forefront of technological advancement in our field by implementing clustering models to derive better metrics and models and eventually bringing AI-based solutions helping us to be the most accurate solution and to be the best support for patients.
The web portal was finalized for clinician use, supporting remote monitoring, test management, and reporting. Clinicians can access both medical and family-friendly reports, enhancing communication and care decisions. Additionally, a CE Class IIa medical certification was secured for the diagnostic tool, supported by a robust Quality Management System (QMS) aligned with ISO 13485 standards.
On the data integration front, the platform achieved readiness for interoperability with Electronic Patient Record (EPR) systems using the HL7 FHIR framework, tested successfully in simulated environments. The Pathway Management System (PMS), initially conceived as a flagging tool, was extended into a system-wide care pathway manager, offering real-time insights and clinical decision support.
These achievements position the VR4NEURO platform as a clinically validated, scalable, and interoperable digital toolset for neurological diagnostics and rehabilitation.
The project’s outcomes also include CE Class IIa certification and ISO 13485 compliance, confirming readiness for clinical deployment across Europe. The introduction of the Pathway Management System, evolved from a simple flagging feature, now provides real-time oversight of patient journeys, offering clinicians decision support and health systems a means to optimize care delivery.
The platform’s impact is multi-fold: enabling earlier intervention, reducing diagnostic bottlenecks, enhancing rehabilitation adherence, and facilitating data-driven care coordination. For broader uptake, key needs include: (1) expanded clinical studies covering additional neurodevelopmental profiles (e.g. ASD), (2) demonstration pilots in diverse health systems, (3) support for international market access and regulatory harmonization (e.g. FDA), and (4) sustained IPR management to protect software and algorithm innovations.
Further, financing is essential to scale commercial readiness and integrate the platform with national health systems. Engaging with payers and regulators will support reimbursement alignment and accelerate clinical adoption. VR4NEURO now stands as a validated, scalable foundation for the digital transformation of neurodiagnostics and rehabilitation, poised for international growth and long-term impact.